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Abstract: The use of human dental pulp stromal cells (hDPSCs) has gained increasing attention as 
an alternative stem cell source for bone tissue engineering. The modification of the cells’ epigenetics 
has been found to play an important role in regulating differentiation, with the inhibition of histone 
deacetylases 3 (HDAC3) being linked to increased osteogenic differentiation. This study aimed to 
induce epigenetic reprogramming using the HDAC2 and 3 selective inhibitor, MI192 to promote 
hDPSCs osteogenic capacity for bone regeneration. MI192 treatment caused a time–dose-dependent 
change in hDPSC morphology and reduction in viability. Additionally, MI192 successfully aug-
mented hDPSC epigenetic functionality, which resulted in increased histone acetylation and cell 
cycle arrest at the G2/M phase. MI192 pre-treatment exhibited a dose-dependent effect on hDPSCs 
alkaline phosphatase activity. Quantitative PCR and In-Cell Western further demonstrated that 
MI192 pre-treatment significantly upregulated hDPSCs osteoblast-related gene and protein expres-
sion (alkaline phosphatase, bone morphogenic protein 2, type I collagen and osteocalcin) during 
osteogenic differentiation. Importantly, MI192 pre-treatment significantly increased hDPSCs extra-
cellular matrix collagen production and mineralisation. As such, for the first time, our findings show 
that epigenetic reprogramming with the HDAC2 and 3 selective inhibitor MI192 accelerates the os-
teogenic differentiation of hDPSCs, demonstrating the considerable utility of this MSCs engineering 
approach for bone augmentation strategies.  
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human dental pulp stromal cells 
 
1. Introduction 
An increasing number of people suffer from bone damage or loss caused by trau-
matic injury, tumour resection or common age-associated diseases such as osteoporosis 
[1], and this is expected to rise in the future, due to increasing life expectancy. Although 
bone has the intrinsic ability for self-repair and regeneration, bone damage reaching a 
critical size potentially results in non-union or permanent defects requiring surgical inter-
vention [2,3]. The annual cost of musculoskeletal disorders to the UK Health Service is 
£4.76 billion [4]. Thus, the ability to generate new bone is still a major clinical need which 
creates an enormous social and economic burden. Current clinical therapies such as auto-
grafts are seen as the gold standard [5,6], however, these procedures are highly invasive, 
with limited tissue availability and inducing donor site morbidity [7,8]. Consequently, 
extensive research has been conducted in the tissue engineering field to meet the rising 
demand for clinically relevant bone tissue. The key to tissue engineering approaches is to 
effectively control the lineage-specific differentiation of mesenchymal stromal cells 
Citation: Man, K.; Lawlor, L.; Jiang, 
L.-H.; Yang, X, B. The Selective  
Histone Deacetylase Inhibitor MI192  
Enhances the Osteogenic  
Differentiation Efficacy of Human 
Dental Pulp Stromal Cells. Int. J. 
Mol. Sci. 2021, 22, 5224. https:// 
doi.org/10.3390/ijms22105224 
Academic Editor: Mikihito Kajiya 
Received: 21 April 2021 
Accepted: 12 May 2021 
Published: 14 May 2021 
Publisher’s Note: MDPI stays neu-
tral with regard to jurisdictional 
claims in published maps and institu-
tional affiliations. 
 
Copyright: © 2021 by the authors. Li-
censee MDPI, Basel, Switzerland. 
This article is an open access article 
distributed under the terms and con-
ditions of the Creative Commons At-
tribution (CC BY) license (http://crea-
tivecommons.org/licenses/by/4.0/). 
Int. J. Mol. Sci. 2021, 22, 5224 2 of 17 
 
 
(MSCs) [9,10]. Bone marrow derived MSCs have been extensively utilised for bone aug-
mentation strategies, however, there has been limited clinical success due to issue includ-
ing low procurement yield, extensive in vitro expansion required and their inherent het-
erogeneity [11,12]. Human dental pulp stromal cells (hDPSCs) have garnered increasing 
interest as an alternative MSC source for use in bone tissue engineering due to the ease of 
tissue extraction, their high proliferation rate and multipotency [13,14].  
In recent years, several cell engineering approaches have been investigated to en-
hance the efficacy of MSCs for bone augmentation strategies. Methods such as gene ther-
apy have provided much excitement within the field [15], however, due to the low process 
efficacy, cost-intensiveness and the potential risk of virally induced tumorigenicity [16], 
alternative methods of controlling MSCs osteogenesis have been explored. It has become 
increasingly apparent that epigenetics plays a significant role in regulating cell fate. Spe-
cifically, researchers have demonstrated that post-translational modifications such as the 
process of acetylation results in alterations in the chromatin structure. This ultimately af-
fects the transcriptional activity of the cell via two groups of histone-modifying proteins, 
histone acetyltransferase (HAT) and histone deacetylase (HDAC) [17]. HAT is responsible 
for the acetylation of histones, which results in the opening of the chromatin structure, 
increasing the cells’ transcriptional activity, while histone deacetylation by HDAC leads 
to transcriptional repression via condensation of the chromatin. Such modifications have 
been showed to affect MSC functions such as multipotency and differentiation potential 
[17,18].  
To date, HDAC inhibitors (HDACi) such as Romidepsin and Vorinostat (SAHA) 
have been approved by the Food and Drug Administration (FDA) for the treatment of 
cutaneous T-cell lymphoma [19]. HDACis can deregulate the epigenetic process and in-
duce hyperacetylation resulting in enhancing gene transcription, promoting MSC osteo-
genic differentiation [20–23]. Although these approaches have shown promise, the use of 
non-selective panHDACis is associated with limitations such as unwanted side effects and 
reduced differentiation efficacy by targeting a broad range of HDAC isoforms [24]. Hence, 
there is a growing precedence to move towards using a more selective approach. Studies 
have reported the role of HDAC3 in regulating osteogenic differentiation by acting as a 
co-repressor of RUNX2, a transcription factor responsible for modulating osteocalcin pro-
duction, known to be essential for bone formation [25]. MI192 is a novel benzamide de-
rivative and a selective HDAC2 and 3 inhibitor, which has demonstrated its potential use 
in the treatment of leukaemia and rheumatoid arthritis [26,27]. Moreover, we have previ-
ously demonstrated the increased efficacy of MI192 on promoting the osteogenic differ-
entiation of adipose-derived MSCs (ADSCs) when compared to the use of the panHDACi 
Trichostatin A (TSA) [28]. Therefore, in this study we investigated the effects of augment-
ing hDPSCs epigenetic functionality with the HDAC2 and 3 selective inhibitor MI192 to 
enhance its efficacy for bone tissue engineering (Figure 1). 




Figure 1. Experimental outline investigating the effects of altering hDPSCs epigenetic functionality 
with MI192 on their osteogenic capacity. 
2. Results 
2.1. MI192 Affects hDPSCs Morphology and Viability 
The hDPSCs were treated with various concentrations of MI192 and incubated for up 
to 72 h. Following 24 h of culture, untreated hDPSCs exhibited a typical fibroblast-like 
morphology (Figure 2A). MI192 at low concentrations (1 and 5 μM) induced a slight elon-
gation in the cell morphology and at higher doses (>10 μM), there was a concentration-
dependant reduction in cell density. Treatment with MI192 at high concentrations (>10 
μM) for 48 and 72 h resulted in a time–dose-dependent decrease in cell density, with an 
increasing number of floating cells observed. AlamarBlue assay showed that MI192 
caused a time–dose-dependent reduction in hDPSCs metabolic activity when compared 
to the untreated cells (Figure 2B). Treatment with MI192 at concentrations of ≥20 μM for 
24 h, ≥5 μM for 48 h and ≥1 μM for 72 h significantly reduced hDPSCs metabolic activity 
compared to that in the untreated cells (p ≤ 0.05). 




Figure 2. Effects of MI192 on hDPSCs morphology and viability. (A) hDPSCs morphology. Scale 
bar = 100 μm. (B) Metabolic activity of hDPSCs, quantified with the AlamarBlue assay. Data are 
expressed as mean ± SD (n = 3). * p ≤ 0.05. 
2.2. MI192 Altered hDPSCs HDAC Activity and Histone Acetylation 
Treatment with 1–50 μM MI192 for 24 and 48 h led to a significant reduction in hDP-
SCs HDAC activity (≥3.4-fold and 4.1-fold, respectively) compared to that of the untreated 
cells in a dose-dependent manner (p ≤ 0.001) (Figure 3A). Moreover, 1 week post MI192 
treatment for 24 and 48 h, the HDACi treated cells exhibited a similar significant reduction 
in HDAC activity (≥1.95-fold and 2.25-fold) compared to the untreated cells in a dose-
dependent manner (p ≤ 0.001) (Figure 3B). MI192 treatment for 24 h caused a dose-de-
pendent reduction in the histone acetylation levels, where MI192 at concentrations greater 
than 20 μM significantly decreased the acetylation levels (≥1.2-fold) compared to that in 
the untreated cells (p ≤ 0.05) (Figure 3C). However, MI192 treatment for 48 h led to a sig-
nificant and dose-dependent increase in the histone acetylation levels (≥1.4-fold) com-
pared to that in the untreated cells (≤10 μM, p ≤ 0.05) (≥20 μM, p ≤ 0.01). One week post 
MI192 treatment for 24 and 48 h, the HDACi treated cells displayed a significant dose-
dependent increase in histone acetylation levels (≥1.45-fold and 1.95-fold) when compared 
to the untreated control (p ≤ 0.01–0.001) (Figure 3D). 




Figure 3. The influence of MI192 on hDPSCs epigenetic functionality. HDAC activity levels (A) immediately post MI192 
treatment and (B) 1 week post MI192 treatment. H3K9 histone acetylation levels (C) immediately post MI192 treatment 
and (D) 1 week post MI192 treatment. Data are expressed as mean ± SD (n = 3). * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. 
2.3. MI192 Halts hDPSCs Cell Cycle Progression 
The effects of MI192 treatment (2 μM) on hDPSCs cell cycle progression was assessed 
following treatment for 24, 48 and 72 h using flow cytometry. The percentage of cells dis-
tributed within the different phases of the cell cycle is shown in Figure 4. 
 
Figure 4. Effects of MI192 treatment on hDPSCs cell cycle progression. Data are expressed as mean 
± SD (n = 3). The significance levels shown are the test group compared to the basal control for that 
time point. * p ≤ 0.05, ** p ≤ 0.01 and *** p ≤ 0.001. 
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2.3.1. G0/G1 Phase 
At 24 h, there was a non-significant reduction in the percentage of MI192 treated cells 
in the G0/G1 phase (50%) compared to the untreated group (59%) (p > 0.05). However, at 
48 h, the number of cells significantly decreased in the MI192 treatment group (52%) com-
pared to the control group (78%) (p ≤ 0.01). A similar pattern was observed at 72 h, with 
MI192 treatment (82%) significantly reducing the percentage of cells compared to the con-
trol group (52%) (p ≤ 0.05). 
2.3.2. G2/M Phase 
The proportion of cells in the G2/M phase within the MI192 treatment group (22%) 
was significantly increased compared to the control group (15%) at 24 h (p ≤ 0.05). At 48 
h, the MI192 treated cells (19%) continued to exhibit a significantly enhanced percentage 
compared to the control group (6%) (p ≤ 0.001), and at 72 h, a similar trend was observed 
where MI192 treatment (23%) substantially increased the percentage of cells in the G2/M 
phase compared to the control group (6%) (p ≤ 0.001). 
2.3.3. S Phase 
After 24 h, MI192 treatment (28%) induced a non-significant increase in the percent-
age of cells in the S phase compared to the control group (26%) (p > 0.05). At 48 h, a signif-
icant increase was observed in the MI192 group (29%) compared to the control group 
(15%) (p ≤ 0.01). At 72 h, the MI192-treated cells (23%) maintained a significant enhance-
ment compared to the untreated cells (12%) (p ≤ 0.001). 
2.4. MI192 Exhibited a Dose-Dependent Effect on hDPSCs alkaline phosphtase (ALP) Activity 
The effects of MI192 treatment on hDPSCs osteogenic differentiation was initially 
evaluated by quantifying ALP specific activity (ALPSA). Cells were treated with 1, 2, 5 
μM MI192 for 48 h before osteoinductive culture for 14 days. Pre-treatment with all MI192 
concentrations significantly enhanced ALPSA (≥1.29-fold) compared to the untreated cells 
(p ≤ 0.01) (Figure 5). Treatment with 2 and 5 μM MI192 elicited a 1.68 and 1.62-fold increase 
in ALPSA levels compared to the untreated group (p ≤ 0.01), however, no statistical dif-
ference was observed between the groups (p > 0.05). Therefore, a pre-treatment regimen 
of 2 μM MI192 for 48 h prior to osteoinductive culture was used for the rest of this study.  
 
Figure 5. Effect of MI192 pre-treatment on hDPSCs ALPSA. Cells were pre-treated with/without 
MI192 for 48 h before culture in osteogenic conditions for 14 days. Data are expressed as mean ± 
SD (n = 3). ** p ≤ 0.01. 
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2.5. MI192 Promoted the Osteogenic Gene and Protein Expression in hDPSCs 
The effects of MI192 pre-treatment on hDPSCs osteoblast-related gene and protein 
expression were examined by RT-qPCR and ICW, respectively (Figure 6). The MI192 pre-
treated groups exhibited a slight non-significant increase in ALP mRNA expression com-
pared to that in the untreated cells at day 3, 7 and 14 (p > 0.05) (Figure 6A). However, on 
day 21, ALP mRNA levels were significantly enhanced in the MI192 pre-treated cells com-
pared to that of the untreated group (p ≤ 0.01). The ALP protein expression was signifi-
cantly and consistently upregulated in the MI192 pre-treated cells on days 7, 21 and 28 
(1.35, 1.48 and 1.51-fold, respectively) compared to that in the untreated group (p ≤ 0.01, 
days 7 and 21) (p ≤ 0.001, day 28) (Figure 6B). The MI192 pre-treated cells exhibited a sig-
nificant increase in bone morphogenic protein 2 (BMP2) mRNA expression from day 3 
through day 21 (1.15, 1.28, 1.23 and 1.18-fold, respectively) (p ≤ 0.01, day 14) (p ≤ 0.001, day 
3, 7 and 21) compared to the untreated cells (Figure 6A). Similarly, the BMP2 protein ex-
pression was significantly upregulated in the MI192 pre-treated group compared to that 
in the untreated cells at days 21 and 28 (2.16 and 1.35-fold, respectively) (p ≤ 0.01) (Figure 
6B). The MI192 pre-treated group exhibited a non-significant increase in type I collagen 
(COL1A) mRNA expression levels compared to the untreated group at days 3, 7 and 21 (p 
> 0.05) (Figure 6A). However, a significant enhancement in the COL1A mRNA expression 
levels was observed in the MI192 pre-treated group at day 14 (1.14-fold) compared to that 
in the untreated cells (p ≤ 0.01). The Col1a protein expression was significantly upregu-
lated in the MI192 pre-treated cells on days 7, 14, 21 and 28 (2.24, 1.71, 3.15 and 2.17-fold, 
respectively) compared to the untreated group (p ≤ 0.01, days 7, 21 and 28) (p ≤ 0.001, day 
14) (Figure 6B). Osteocalcin (OCN) mRNA expression levels in the MI192 pre-treated cells 
were significantly enhanced by 1.95-fold on day 7 (p ≤ 0.001), 1.81-fold on day 14 (p ≤ 0.001) 
and 1.17-fold on day 21 (p ≤ 0.001) compared to the untreated group (Figure 6A). The OCN 
protein expression level was significantly elevated in the MI192 pre-treated group (2.12, 
1.15, 1.26 and 1.4-fold, respectively) compared to that in the untreated cells on days 7, 14, 
21 and 28 (p ≤ 0.01, days 7, 14 and 21) (p ≤ 0.001, day 18) (Figure 6B). 




Figure 6. The effects of MI192 pre-treatment (2 μM MI192 for 48 h) on hDPSCs osteogenic differentiation and mineralisa-
tion. Osteoblast-related (A) gene expression, (B) protein production, (C,D) calcium deposition (scale bar = 100 μm)) (day 
28) and (E) mineral nodule formation (day 28) (scale bar = 50 μm). Data are expressed as mean ± SD (n = 3). ** p ≤ 0.01 and 
*** p ≤ 0.001. 
2.6. MI192 Enhanced hDPSCs Extracellular Matrix Mineralisation 
The effects of MI192 pre-treatment on hDPSCs extracellular matrix calcium deposi-
tion was identified via Alizarin red staining. MI192 substantially enhanced hDPSCs aliz-
arin red staining for calcium deposition compared to that in the untreated cells (Figure 
6C). Following semi-quantitative analysis, it was confirmed that the MI192 pre-treated 
group exhibited a significant increase in calcium deposition (4.75-fold) compared to that 
in the untreated cells (Figure 6D) (p ≤ 0.001). Von Kossa analysis was performed to assess 
the formation of mineral nodules in the extracellular matrix. A substantial increase in min-
eral nodules (black staining) was observed within the MI192 pre-treated cells compared 
to that in the control group (Figure 6E). Additionally, enhanced Van Gieson’s staining for 
collagen deposition (pink staining) was observed in the MI192 pre-treated group, partic-
ularly situated in close proximity to Von Kossa positive mineral nodules. 




Epigenetic approaches for tissue engineering have gained increasing attention due to 
their ability to modulate cellular functions without altering the DNA sequence. An in-
creasing number of reports have demonstrated the feasibility of using HDACis to enhance 
the osteogenic potential of MSCs [29,30]. However, the majority of these studies have uti-
lised non-selective panHDACis, which are associated with reduced efficacy and potential 
side effects [24]. The HDAC3 isoform has been shown to be linked to osteogenic differen-
tiation due to its repression of the osteogenic transcription factor RUNX2 [31]. MI192 en-
hanced selectivity for HDAC2 and 3 isoforms has increased its efficacy for different clini-
cal applications [26,27], hence, the use of this selective approach may promote the clinical 
utility of MSC-based therapies for bone tissue engineering applications. 
HDPSCs have garnered growing interest for use in bone tissue engineering, due to 
their ease of procurement, increased proliferation rate and osteogenic capacity [13,32]. 
Therefore, the combination of this stem cell source with HDACi treatment could further 
accelerate the fracture healing process which would have a tremendous impact in the clin-
ical practice. Several studies have reported the ability of HDACis to initiate cell death, 
which is key to their utility in cancer therapeutics [30,33]. To enhance the safety and effi-
cacy of HDACi-based therapeutics, a clearer understanding of the effects of these epige-
netic regulators on normal cells [34], in particular on MSCs, is essential for clinical trans-
lation. The findings of this study showed that MI192 treatment caused a time–dose-de-
pendent reduction in the viability of hDPSCs. Boissinot et al. (2012) showed a similar pat-
tern with MI192 inducing a time–dose-dependent reduction in the viability of leukemic 
cell lines (HL60, Kasumi-1 and U937) [26]. These findings suggest that MI192 impact on 
cell viability is not only limited to cancer cell lines but also stem cells, an important con-
sideration for the use in MSCs-based tissue engineering. 
Several studies suggest that HDACis can arrest cells in various stages of the cell cycle 
[35,36]. Additionally, it has been reported that the HDAC2 and 3 isoforms are involved in 
regulating cell cycle progression [37,38]. In the present study, treatment with 2 M MI192 
caused a time-dependent reduction in the accumulation of cells in the G0/G1 phase but 
increased the percentage of cells in the S and G2/M phase. Jiang et al. (2014) described 
similar results, where adult neural stem cells with reduced expression of HDAC3 were 
unable to pass the G2/M phase, indicating the role of HDAC3 in controlling the cell cycle 
progression through this phase [38]. Treatment with 2 M MI192 was shown to exhibit 
limited toxicity from the viability assessment, thus it is probable that the effects on cell 
cycle progression is associated with halting cellular proliferation, therefore priming cells 
for differentiation, and leading to cell synchronization rather than initiating cell death. 
Since MSCs are highly receptive to epigenetic changes [39], the use of HDACis may 
provide a valuable approach to enhance the efficacy of MSCs-based therapies for bone 
tissue engineering applications. Therefore, it is important to elucidate the mechanism in 
which MI192 regulates hDPSCs epigenetic functionality. In this study, MI192 treatment 
significantly reduced the HDAC activity in a time–dose-dependent manner compared to 
untreated cells. This correlated with the effects of MI192 on HeLa and PC3 cells [26,40], 
where treatment with 10 μM MI192 for 24 h reduced HDAC activity by 49% compared to 
the untreated group. Our results showed a reduction of 83% in HDAC activity after 24 h 
treatment with 10 μM MI192, indicating MSCs may be more sensitive to MI192 compared 
to the transformed cells. Following 1-week post 24 and 48 h of MI192 treatment, the 
HDACi treated cells continued to exhibit a significant reduction in the HDAC activity 
when compared to the untreated cells (~49% reduction). The prolonged inhibitory effect 
of this compound is likely due to the slow binding kinetics of MI192, correlating with the 
observations reported by Boissinot et al. [26]. More importantly, our data showed that the 
HDAC inhibition induced by MI192 after 48 h resulted in a positive enhancement on his-
tone H3K9 acetylation. The increased H3K9 acetylation represents a transcriptionally per-
missive chromatin structure which has been reported to enhance gene expression [41,42], 
therefore, the introduction of osteogenic growth factors to cells with a transcriptionally 
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active/open chromatin structure will likely enhance growth factor induced differentiation 
efficacy within hDPSCs. Moreover, it has been reported that hyperacetylation promotes 
the transcriptional activity of Runx2. Jeon et al. (2006) showed that Runx2 hyperacetyla-
tion enhanced the activity and stability of this transcription factor via protection from 
smurf-1 mediate degradation [43]. Hence, it is likely the MI192 induced hyperacetylation 
within hDPSCs enhanced the transcriptional activity of Run2, however, this would re-
quire further investigation. Importantly, it was also confirmed that the prolonged HDAC 
inhibition observed after 1 week of culture resulted in increased histone acetylation levels 
within the MI192 pre-treated cells. This indicates the slow on/off binding kinetics of MI192 
[26], potentiating the effects of the altered epigenome on hDPSCs osteogenic differentia-
tion. Taken together, these results confirm that MI192 is an effective epigenetic regulator 
within hDPSCs, and the augmented epigenome induced by HDACi treatment potentially 
indicates the increased differentiation capacity of these cells. 
HDACis have been shown to alter the expression of osteoblast-related markers in 
MSCs by regulating their epigenetic functionality [20,30,44]. In this study, the effects of 
MI192 pre-treatment on the expression of osteoblast-related genes and proteins were in-
vestigated. Our finding showed that MI192 significantly upregulated hDPSCs BMP2 ex-
pression levels throughout osteogenic culture. Phimphilai et al. (2006) proposed that BMP 
signalling is an essential component to RUNX2-dependent osteogenesis [45], and Hu et 
al. (2013) confirmed this in ADSCs with the addition of BMP antagonist, Noggin, resulting 
in a decrease in the RUNX2 mRNA expression level [46]. Therefore, the upregulation in 
BMP2 expression levels, induced by MI192 treatment, indicates the HDACis role in stim-
ulating hDPSCs early phase osteogenic differentiation. Studies have also reported that 
BMP2 levels increases steadily throughout hDPSC osteogenesis [30,47], correlating with 
the mRNA expression profiles in this study. MI192 pre-treatment also upregulated the 
gene and protein expression of ALP, which was confirmed by the corresponding func-
tional ALPSA assay. The mRNA and protein expression levels of COL1A, known to be a 
key component of the bone extracellular matrix [48], was significantly upregulated in the 
MI192 pre-treated hDPSCs throughout osteogenic culture, indicating the role of MI192 in 
accelerating the maturation of the extracellular matrix. Additionally, MI192 promoted the 
OCN levels when compared to untreated cells, indicating that MI192 pre-treatment is ca-
pable of promoting hDPSC osteogenic maturation. Piano et al. (2014) reported that 
valproic acid (VPA) pre-treated hDPSCs exhibited significantly reduced OCN mRNA and 
protein expression, indicating that VPA inhibited osteogenic maturation. Additionally, 
this group demonstrated that silencing HDAC2 inhibited the expression of OCN in Saos-
2M osteosarcoma cell line, suggesting the importance of HDAC2 in regulating the OCN 
expression [30,49]. In the present study, we did not observe this downregulation in the 
OCN expression following MI192 pre-treatment, likely due to the selective inhibition of 
MI192 on HDAC3, which VPA does not possess. Schroeder et al. (2004) reported the im-
portance of the RUNX2-HDAC3 complex in regulating the mRNA and protein expression 
of OCN [25]. Due to MI192 selective inhibition of HDAC3, this probably alleviates HDAC3 
repression of RUNX2, leading to increased activity and stability of this transcription factor 
[42], although this would require further investigation. Taken together, these results show 
that hyperacetylation induced by MI192 pre-treatment increase the expression of hDPSCs 
osteoblast-related markers, consistent with several studies in the literature [50–52]. Alt-
hough enhanced expression levels of osteoblast-related genes and proteins was observed 
in the MI192 pre-treated hDPSCs, it is likely HDACi-induced epigenetic modification al-
tered the processing of transcribed mRNA into function proteins through altered RNA 
splicing/microRNA expression [53,54], which would also be of interest to be elucidated in 
future studies. Additionally, it is important to note that the elevated osteogenic capacity 
induced by MI192 pre-treatment is likely due to a combination of enhanced accessibility 
to genes of interest via increased chromatin transcriptional activity and transcription fac-
tor activation via hyperacetylation and HDAC isoform inhibition. 
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The effects of MI192 pre-treatment on calcium deposition and mineralisation were 
assessed with Alizarin red and Von Kossa staining, respectively [55]. MI192 substantially 
enhanced extracellular matrix collagen deposition and mineralisation compared to the 
untreated hDPSCs, correlating with the increased mineralisation observed in MI192 pre-
treated ADSCs [28]. These findings clearly indicate that MI192 effects in stimulating  
hDPSCs efficacy for bone formation is not limited to enhancing osteogenic differentiation 
but also the mineralisation of its extracellular matrix, consistent with observations in the 
literature [32,56]. Moreover, the enhanced collagen production and calcium deposition 
observed in this study indicate the efficacy of MI192 pre-treatment in promoting hDPSCs 
mineralisation, likely due to the slow-binding kinetics of this HDACi [26]. The effective-
ness of this pre-treatment strategies enhances the utility of MI192 in cell-based therapies 
for bone augmentation strategies. 
In the present study, we examined the influence of altering hDPSCs epigenetic func-
tionality with the HDAC2 and 3 selective inhibitor, MI192, in promoting their efficacy for 
bone augmentation strategies. We have shown that MI192 is an effective epigenetic regu-
lator within hDPSCs, augmenting key cellular processes including metabolic activity and 
cell cycle progression through HDACi induced hyperacetylation. Importantly, we have 
demonstrated that utilising a pre-treatment regimen, MI192 accelerated the osteogenic 
differentiation and mineralisation rate of hDPSCs, enhancing its bone formation capacity. 
Future studies would be required to further examine the influence of MI192 treatment on 
stimulating bone regeneration in vivo. 
4. Materials and Methods 
4.1. Cell Culture 
HDPSCs were isolated from sound third molars obtained with patients’ consent 
through the Leeds Dental Institute Research Tissue Bank (REC 07/H1306/93), with ethical 
approval (180,615/km/173) [13]. HDPSCs were isolated using the collagenase digestion 
method previously described by Tomlinson et al. (2015) [57]. Cells were subsequently cul-
tured in a basal medium consisting of alpha modified minimum essential medium (α-
MEM, Lonza, Manchester, UK) supplemented with 10% fetal calf serum (FCS, Lonza, 
Manchester, UK), 2 mM L-glutamine and a mix of 100 units/mL penicillin with 100 μg/mL 
streptomycin at 37 °C in 5% CO2. Cells were passaged when reaching approximately 80% 
confluence, and hDPSCs of up to passage 4 were used for all experiments. 
4.2. Cell Viability Assay and Morphological Assessment 
For cell viability assays, hDPSCs were plated at 1 × 104 cells per well within a 96-well 
plate in basal medium and incubated for 24 h. Media was then replaced with fresh basal 
media supplemented with MI192 at a range of concentrations (1, 5, 10, 20, 50 μM) and 
incubated for 24, 48 and 72 h. Basal medium alone was used as the control. Then, 20 μL of 
AlamarBlue reagent (Thermo Scientific, Paisley, UK) was added to each well and incu-
bated for 4 h at 37 °C. Fluorescence readings were acquired using a Varioskan Flash Mul-
timode Microplate Reader (Thermo Scientific, Paisley UK) at an excitation wavelength of 
540 nm and emission wavelength at 590 nm. For cell morphological assessment, hDPSCs 
were seeded at 1 × 105 cells per well in a 24-well plate and incubated for 24 h, after which 
the same treatment regime was utilised where the cell morphology was visualised by in-
verted microscopy (ZEISS, AX-100). 
4.3. DNA Quantification 
DNA content was determined by Quant-iT PicoGreen dsDNA Assay Kit (Invitrogen, 
Life Technologies, Paisley, UK) according to the manufacturer’s instructions. Briefly, cells 
were washed twice with phosphate-buffered saline (PBS, Lonza, Manchester, UK) and 
lysed following three freeze–thaw cycles in 0.1% Triton X-100 (Sigma-Aldrich, Gilling-
ham, UK) in PBS. Then, 10 μL of cell lysate was added to 90 μL of TE buffer (10 mM Tris-
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HCl, 1 mM EDTA) into a 96-well plate (Corning, Deeside, UK). Next, 100 μL of PicoGreen 
reagent was added to all samples and then incubated in the dark for 5 min. The fluores-
cence was measured in a Varioskan Flash Multimode Microplate Reader at 480 nm exci-
tation and 520 nm emission. 
4.4. HDAC Activity 
Cells were cultured in two 96-well plates (1 × 104 cells per well) in basal medium 
containing MI192 at a range of concentrations (1, 5, 10, 20, 50 μM). Basal medium alone 
was used as the control. At 24 and 48 h, the HDAC activity in the cells was measured 
either measured immediately post treatment or following 1 week in basal culture using 
an InSitu HDAC Activity Fluorometric Assay Kit (Cambridge BioSciences, Cambridge , 
UK) according to the manufacturer’s instructions. Briefly, incubation media was replaced 
with 100 μL of reaction mix containing HDAC substrate and incubated for 3 h at 37 °C. 
Following which, 100 μL of lysine developer was added to the plate and incubated for a 
further 30 min at 37 °C. The fluorescence was measured in a Varioskan Flash Multimode 
Microplate Reader at an excitation wavelength of 368 nm and emission wavelength at 442 
nm. HDAC activity was normalised with DNA content.  
4.5. Histone Acetylation 
Detection of H3K9 histone acetylation was assessed using the EpiQuik In Situ His-
tone H3-K9 Acetylation Assay Kit (Epigentek, Farmingdale, NY, USA). Cells were cul-
tured in basal medium containing different concentration of MI192 (1, 5, 10, 20, 50 μM) in 
a 96-well plate. Basal medium alone was used as the control. After treatment for 24 and 
48 h, histone acetylation was performed either immediately post treatment or following 1 
week in basal culture according to the manufacturer’s instructions. The absorbance was 
read on a Varioskan Flash Multimode Microplate Reader at 450 nm within 10 min. Acet-
ylation was normalised to DNA content.  
4.6. Cell Cycle Analysis 
Cells were plated in 6-well plates at 1 × 105 cells per well and cultured in basal me-
dium for 48 h. The medium in the test group was replaced with basal medium containing 
2 μM MI192 and basal medium alone was used as the control. At 24, 48 and 72 h, cells 
were trypsinised, re-suspended with 500 μL of ice-cold 70% (v/v) ethanol/PBS and stored 
in −80 °C for assessment. For staining, the cell suspension was centrifuged at 800 rpm for 
5 min, and the pellet was washed with 500 μL 4 °C FACS buffer: PBS with the addition of 
0.1% (w/v) bovine serum albumin (Sigma-Aldrich, Gillingham, UK) and 0.1% TWEEN-20 
(Sigma-Aldrich, Gillingham, UK). The cell pellet was re-suspended with 500 μL of freshly 
made staining solution (20 μg/mL propidium iodide (Sigma-Aldrich, Gillingham, UK) 
and 200 μg Ribonuclease A (Sigma-Aldrich, Gillingham, UK)) and incubated for 20 min 
at room temperature. Cells were then placed on ice for assessment with Attune NxT Flow 
Cytometer (Life Technologies, Paisley, UK). Subsequent cell cycle analysis was under-
taken using ModFit LT software (LT v3, Verity). 
4.7. MI192 Pre-Treatment and Osteogenic Induction  
HDPSCs were cultured in 24-well plates (4 × 104 cells per well) in basal medium for 
24 h. The media was replaced with basal medium containing 2 μM MI192 for 48 h. Basal 
medium alone was used as the control. Following the pre-treatment period, cells were 
washed with basal medium and incubated in osteogenic medium, which consisted of ba-
sal medium supplemented with 50 μM L-ascorbic acid 2-phosphate sesquimagnesium salt 
hydrate (Sigma-Aldrich, Gillingham, UK), 10 mM β-glycerol phosphate (Sigma-Aldrich, 
Gillingham, UK) and 100 nM dexamethasone (Sigma-Aldrich, Gillingham, UK). The me-
dium was changed every 3 days. 
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4.8. Alkaline Phosphatase Specific Activity (ALPSA) Assay 
ALPSA was determined using the 4-nitrophenyl colourimetric phosphate liquid sys-
tem assay (pNPP, Sigma-Aldrich, Gillingham, UK). Briefly, following pre-treatment 
with/without 1, 2 and 5 μM MI192, hDPSCs were cultured in osteogenic medium for two 
weeks, and lysed with 0.1% Triton X-100 in PBS. Then, 90 μL of pNPP was added to 10 μL 
of cell lysate in a 96-well plate (Corning, Deeside, UK) for 30 min at 37 °C in the dark. 
Next, 100 μL of 1 M NaOH was added to each well to stop the reaction, and the absorbance 
was read at 405 nm on a Varioskan Flash Multimode Microplate Reader (Thermo Scien-
tific, Paisley, UK). Alkaline phosphatase activity was normalised to total DNA content.  
4.9. Real-Time Reverse Transcription-Polymerase Chain Reaction (RT-qPCR) 
Cells were pre-treated with/without 2 μM MI192 for 48 h followed by incubation in 
osteogenic medium for up to 28 days. At different time points (days 0, 3, 5, 7, 14, 21 and 
28), cells were collected for RT-qPCR assay. The primers used in this study are listed in 
Table 1. The expression of osteoblast-related genes was assessed using RT-qPCR. RNA 
was extracted using the RNase mini kit (Qiagen, Manchester, UK) according to the man-
ufacturer’s protocol. Then, 200 ng of RNA was transcribed to cDNA using the high capac-
ity RNA to cDNA Kit (Applied Biosystems, Warrington, UK) following the supplier’s in-
structions. Following which, cDNA was amplified using TaqMan primers (Table 1) in a 
20 μL reaction with a 96-well PCR plate (Starlab, Milton Keynes, UK). Amplification oc-
curred within a LightCycler 480 real-time qPCR system (Roche, Welwyn Garden City, 
UK). For each sample, the cycle threshold (Ct) value was acquired, and the comparative 
Ct method (2−∆∆Ct) was utilised to quantify the gene expression levels relative to the house-
keeping gene. 
Table 1. Primers used for TaqMan gene expression assays. 
Gene Symbol Description 






BMP2 Bone morphogenetic protein 2 Hs00154192_m1 
ALPL Alkaline phosphatase Hs01029144_m1 
COL1A1 Collagen, type I Hs00164004_m1 
OCN/BGLAP 
Osteocalcin/PMF-bone gamma-carbox-
yglutamate (gla) protein 
Hs00609452_g1 
4.10. In-Cell Western (ICW) Assay 
The expression of osteoblast-related proteins was assessed using the ICW assay ac-
cording to the manufacturer’s instructions. Briefly, cells were fixed in 10% neutral buff-
ered formalin (NBF, Cellpath, Newtown, UK) for 20 minutes prior to be permeabilised 
with 0.1% Triton X-100 in PBS for 30 min and then blocked with LICOR Odyssey blocking 
buffer (Li-Cor Biosciences, Cambridge, UK) for 1.5 h at room temperature. The samples 
were incubated overnight at 4 °C with primary antibodies to ALP (1:300), COL1A (1:200), 
OCN (1:400) (Abcam, Cambridge, UK) and BMP2 (1:500) (Invitrogen, Life Technologies, 
Paisley, UK) in Odyssey buffer. Samples were washed in PBS containing 0.1% Tween 20 
for five times and then incubated with the IRDye 800CW secondary antibody (1:800) and 
the CellTag 700 stain (1:500; Li-Cor Biosciences, Cambridge, UK) in the Odyssey blocking 
buffer for 1 h at room temperature [58]. The plates were read under the Odyssey SA Im-
aging System (Li-Cor Biosciences, Cambridge, UK) at both 700 and 800 nm. Relative fluo-
rescent intensity (IRDye 800CW) was normalised with cell number (CellTag 700 stain). 
The data were quantified using the Image Studio analysis software (Li-Cor Biosciences: 
v5) [59]. 
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4.11. Alizarin Red Staining and Quantification 
Calcium-rich deposits were visualised using the Alizarin Red solution (Millipore, 
Watford, UK) for 15 min at room temperature, and observed under a Leica DMI6000 B 
inverted microscope. The resulting staining was dissolved in 10% cetylpyridinium chlo-
ride (Sigma-Aldrich, Gillingham, UK) for 1 h. Following this, the absorbance was read at 
550 nm using the Varioskan Flash Multimode Microplate Reader. 
4.12. Von Kossa Staining 
Mineral nodules were identified using the Von Kossa Stain Kit (Atom Scientific, 
Cheshire, UK) according to the manufacturer’s instructions. Briefly, samples were incu-
bated with 10% aqueous silver nitrate solution at room temperature in a UV lightbox for 
10 min. This was followed by incubation with 5% sodium thiosulfate for 5 min and then 
incubated with Van Gieson’s solution for 5 min. The resultant staining was observed un-
der a Leica DMI6000 B inverted microscope. 
4.13. Data Analysis 
For all data presented, experiments were repeated at least three times. All statistical 
analysis was undertaken with IBM SPSS software (IBM Analytics, version 21), using 
ANOVA and post-hoc Tukey’s test for comparisons of multiple groups. p-value equal to 
or lower than 0.05 was considered to be significant. For all graphs: * p ≤ 0.05, ** p ≤ 0.01 
and *** p ≤ 0.001. 
5. Conclusions 
In conclusion, the findings of this study demonstrate that the selective HDAC2 and 
3 inhibitor MI192 is capable of modifying the epigenome of hDPSCs, resulting in promot-
ing its efficacy for bone formation. To the authors knowledge, this is the first study to 
promote the osteogenic capacity of hDPSCs via the use of a selectivity HDACi. Taken 
together, these findings demonstrated the considerable potential of using epige-netic reg-
ulation to enhance the efficacy of MSCs-based therapy for bone regeneration 
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